Vaccine studies in infants < 6 mo with novel vaccine candidates have generally demonstrated poor immunogenicity (90).
«Cholera
vaccine study in Haiti suggests problems with current booster regimen.»
G.K.S. is on a Data and Safety Monitoring Board for a GlaxoSmithKline - funded RSV
vaccine study in pregnant women.
• RV217 (ECHO): HIV - 1 Prevalence, Incidence, Cohort Retention, and Host Genetics and Viral Diversity in High Risk Cohorts in East Africa • Infectious Disease Surveillance (HIV, TB and Malaria) and Cohort Development Among Urban and Rural Communities • Karolinska Institute
vaccine study in Tanzania testing a prime - boost HIV vaccine regimen using unadjuvanted DNA vaccines followed by a Modified Vaccinia Ankara (MVA), which was developed by MHRP and NIAID.
2015 — Began a new Ebola
vaccine study in Abuja, Nigeria, using a monovalent chimpanzee adenovirus Type 3 (ChAd3) candidate developed at the NIAID and being developed by GlaxoSmithKline (GSK), the study sponsor.
1997 — Led the development of HIV vaccines for global deployment — In 1997, MHRP launched the first non-subtype B
vaccine study in Thailand.
Statement from Planned Parenthood Federation of America Senior Director of Medical Services Dr. Deborah Nucatola on New HPV
Vaccine Study in the Journal Pediatrics
Not exact matches
Inovio's
vaccine against HPV is currently
in Phase II clinical
studies, and Kim says «about 50 percent» of the subjects
in that trial are defeating the disease.
But while thousands of clinical trials on immunotherapy drugs, of which many are predicted to fail, are springing up, the depth of information on neoantigen
vaccines is much shallower: Just two
studies on neoantigen
vaccines for melanoma, recently profiled
in Nature, were completed last year
in Boston and Germany.
In 2015, researchers at the University of Washington's Cancer
Vaccine Institute published a
study on designing
vaccines to prevent breast cancer.
There have been some pieces
in recent years
in Time and the NYT, but overall, I see little about it
in the media
in contrast with, say autism or
vaccines, anyway, where any little
study seems to get covered.
In essence, the HPV
vaccine will continue to be advised against during pregnancy until more research confirms what this
study has found.
There are now two rotavirus
vaccines for infants, and
studies indicate a dramatic drop
in the number of new cases.
Not only would the new method, tested only
in mice, be more convenient but also more effective than the flu shot or nasal spray, according to a
study at the International
Vaccine Institute
in Seoul.
Whenever
vaccines are questioned, the name of Dr. Andrew Wakefield and the
study he co-authored
in 1998 are cited and discredited.
In particular, much of our Division's past research has focused on
vaccine studies and investigations into the cause of Kawasaki disease.
A recent
study found a 116 fold increase
in fetal death presumably caused by flu
vaccines.
A well conducted
study published
in the Italian medical journals
in June 2007 demonstrated that the daily intake of Colostrum can be 3x more effective than the flu
vaccine for providing protection.
The manufacturer of the sole dengue
vaccine on the market says a new
study shows that it should only be used
in people who have had a previous infection from the mosquito - borne virus.
A 2016 Pediatrics
study found that, within six years of the first
vaccine's introduction
in 2006, infections with the four HPV types covered decreased 64 percent among 14 - to 19 - year - old girls.
This high variability of influenza virus
in the
study region (and other subtropical / tropical climates) will require improved
vaccines with broader antigenic coverage, the authors report.
There were 111 infant deaths during the
study — 50
in the placebo group and 51
in the
vaccine group; and seven maternal deaths — five
in the placebo group and two
in the
vaccine group.
In the new
study, the method accurately predicted
vaccine efficacy rates for more than 40 years of flu records.
In the new
study, researchers at the NIAID used a virus - like particle
vaccine cocktail that expressed a handful of different subtypes of a key surface protein of the influenza virus: hemagglutinin H1, H3, H5 and H7.
A new
study shows pregnant women who get flu shots regularly have a weaker peak antibody response to the
vaccine than women who don't get them regularly, though mothers and their babies
in both groups were well - protected at the time of delivery.
Published
in The Journal of Rural Health, the
study involved research nurses administering the first dose of the HPV
vaccine series free of charge to Appalachian Kentucky women aged 18 - 26.
In a preliminary study published in the April Journal of the American Medical Association, the researchers found that the vaccine produced by this method protects against the two strains to which the subjects were exposed and most likely protects against the thir
In a preliminary
study published
in the April Journal of the American Medical Association, the researchers found that the vaccine produced by this method protects against the two strains to which the subjects were exposed and most likely protects against the thir
in the April Journal of the American Medical Association, the researchers found that the
vaccine produced by this method protects against the two strains to which the subjects were exposed and most likely protects against the third.
The
study, «The efficacy of the BCG
vaccine against newly emerging clinical strains of Mycobacterium tuberculosis,» was published
in the journal PLOS One
in September.
Study authors intend to perform additional research
in the future to follow up on their estimate of how well the current
vaccines protect against HPV - associated cancers.
Dr Alice Forster,
study author and Cancer Research UK scientist at University College London, said: «Although around 87 per cent of girls
in the UK do have the
vaccine it's concerning to see that some girls from some ethnic minority groups feel they don't need to have it.
Ferris, first author of the new
study who led trials of the quadrivalent
vaccine in 2002, says the earlier, shorter - term evaluation clearly indicated the
vaccine worked.
«
Study offers new recommendations for TB
vaccine testing
in humans.»
The new formula's reduced effectiveness is most likely driving the recent epidemics of pertussis, says the
study's lead author, Nicola Klein, co-director of Kaiser Permanente Vaccine Study Center in Oakland, Ca
study's lead author, Nicola Klein, co-director of Kaiser Permanente
Vaccine Study Center in Oakland, Ca
Study Center
in Oakland, Calif..
At Kaiser Permanente Northern California, which conducted the
study, the first use of the new DTaP was
in the
vaccine's fifth booster shot
in 1991, followed by its use for the fourth booster the next year.
Dr. David Cavanagh, of the University of Edinburgh's School of Biological Sciences, who led the
study, said: «There is a desperate need for an effective
vaccine, which can be made easily
in large quantities, to protect against this devastating disease.
Protection against the disease pertussis, or whooping cough, doesn't appear to be as strong with the currently administered
vaccine when compared with the older version administered up until the 1990s, according to a new
study in Pediatrics.
The
vaccine administered
in the
study was for viral influenza — a disease against which doctors recommend patients be vaccinated annually.
Studies that compare flu alterations
in multiple people won't immediately tell researchers how to design
vaccines, she says, but could point to parts of the virus for further investigation.
For thimerosal, the IOM looked at five
studies, examining populations
in Sweden, Denmark, the United Kingdom, and the United States (
studies that
vaccine critics contend were flawed).
CCR5 should remain «a very important target for
vaccines and drugs,» he says, noting that they have found only one person with the double CCR5 defect
in 300 people
studied so far.
Yet there is reason for optimism: the NIH has already developed a DNA
vaccine against the West Nile virus that appeared promising
in early human
studies (although ultimately the NIH could not find a commercial partner to take that
vaccine forward).
A multi-institutional
study, as reported
in the journal Infection Control and Hospital Epidemiology, shows that mandatory flu
vaccines for healthcare workers improve vaccination rates by as much as 30 percent and reduce absenteeism during critical periods by about six percent.
These
study results highlighting this promising strategy are published
in npj
Vaccines.
Babies inoculated with a commonly used five -
in - one
vaccine to protect against a range of potentially lethal childhood diseases face up to a six-fold increased risk of fever - associated seizures on the day they are vaccinated, according to a
study of nearly 380,000 Danish children.
In the
study, a tipping point represented the point at which
vaccine coverage declines dramatically due to spreading fear, which could cause large disease outbreaks due to a loss of population immunity.
In adults,
studies have suggested that the anthrax
vaccine is quite safe; it's made with inactivated protein from the anthrax bacteria, much like
vaccines that protect against diptheria and tetanus.
«We have followed a less potent neutralizing lineage
in this particular individual before, but now we have found a far more potent antibody and have been able to
study its development over six years,» said first author Mattia Bonsignori, M.D., of the Duke Human
Vaccine Institute.
The company plans
in October to conduct a separate test specifically to
study the seasonal flu
vaccine's effectiveness among 480 elderly participants (a demographic often encouraged to get seasonal flu shots), and Phase III efficacy trials across a larger set of demographics are scheduled to begin early next year.
A resurgence
in whooping cough cases
in the U.S. is likely due to incomplete
vaccine coverage
in the past combined with waning protection from the
vaccine, according to a new
study published
in the March 28 issue of Science Translational Medicine.
«Based on epidemiological
studies, the 9vHPV
vaccine could prevent approximately 90 percent of cervical cancer, 90 percent of HPV - related vulvar and vaginal cancer, 70 to 85 percent of high - grade cervical disease
in females, and approximately 90 percent of HPV - related anal cancer and genital warts
in males and females worldwide,» explained Anna R. Giuliano, Ph.D., Director of the Center for Infection Research
in Cancer at Moffitt.